-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*Only for medical professionals' reference.
Listen to Professor Ye Lefu's talk about prostate cancer! In 1937, the legendary Nanyang overseas Chinese, Mr.
Hu Wenhu, donated funds to build the Fujian Provincial Hospital.
For more than 80 years, after several generations of unremitting efforts, the Fujian Provincial Hospital has developed into a clinical diagnosis and treatment, medical research, medical education, and preventive health care provider in Fujian Province.
center.
In 1972, under the leadership of Professor Chen Zifu, the Department of Urology of Fujian Provincial Hospital was established as an independent department.
After decades of development, the Department of Urology has grown and developed.
The quality of minimally invasive surgery has reached the domestic advanced level, ranking the leading position in the province.
Overseas Chinese patients return home for diagnosis and treatment.
"At present, our department has 3 wards, more than 140 beds, more than 40 doctors, and the sub-specialties are very complete, and we have recently resumed kidney transplantation related work.
" Professor Ye Lefu, deputy director of the Department of Urology, Fujian Provincial Hospital introduced Tao.
As an expert in urology at Fujian Provincial Hospital, Professor Ye Lefu has rich experience in diagnosis and treatment of various urinary diseases, especially prostate cancer.
He introduced to us the characteristics of the department and the status quo and challenges of prostate cancer diagnosis and treatment.
Advanced technology makes treatment the icing on the cake.
The Department of Urology, Fujian Provincial Hospital is one of the first domestic urological laparoscopic surgery units to carry out transabdominal pathways.
It is the first in Fujian Province to carry out laparoscopic nephron-sparing nephrectomy and giant adrenal tumor resection.
Minimally invasive techniques such as surgery and laparoscopic inguinal lymph node dissection.
Professor Ye Lefu introduced that the current department focuses on minimally invasive surgery and has formed its own characteristics.
"We have carried out some complicated kidney-saving operations early on, such as ultrasound-guided partial nephrectomy, laparoscopic radical cystectomy, total laparoscopic urinary diversion, and so on.
In October 2020, the Department of Urology introduced the province’s first fourth-generation Da Vinci robot (XI).
Professor Ye Lefu led the team to carry out three consecutive partial nephrectomy procedures, marking the entry of the Department of Urology of Fujian Provincial Hospital The era of robotic surgery.
"After the practice of surgery, I feel that the Da Vinci robot can make the surgery more minimally invasive, further reduce the complications of the surgery, and the patient recovers faster.
"In the treatment and scientific research of urinary system tumors, Professor Ye Lefu’s team is also actively carrying out scientific research and research on molecular classification, neoadjuvant chemotherapy, postoperative adjuvant therapy, and neoadjuvant endocrine therapy for prostate cancer.
Better treatment.
Early screening and early benefit.
Among all prostate diseases, prostate cancer is especially popular among elderly men, and it has gradually become a major stubborn disease that endangers the health of elderly men.
Prostate cancer is the second most common disease in men worldwide.
Common malignant tumors are also the fifth most common cause of cancer-related deaths in men [1].
Professor Ye Lefu introduced that most of the prostate cancer patients in the Department of Urology of Provincial Hospitals are middle-advanced patients, and relatively few early-stage patients.
But with With the improvement of people’s awareness of screening and the advancement of screening methods in recent years, the number of patients with early prostate cancer has gradually increased.
"In general, the age of onset has a trend of getting younger, and the incidence has gradually increased.
the trend of.
"Professor Ye Lefu said that early radical treatment of patients with surgery or radiotherapy can achieve very good therapeutic effects, and even some early patients can continue to benefit by adopting close follow-up.
"The current difficulty is targeting local areas.
Advanced or metastatic prostate cancer.
For patients with locally advanced prostate cancer, comprehensive treatment can be used; for advanced patients, long-term treatment based on endocrine therapy is recommended; for patients with metastatic castration-resistant prostate cancer (mCRPC), the current treatment effect is not ideal Although there are many new drugs coming out, the prognosis of patients is not good.
"Professor Ye Lefu concluded.
With the advent of new drugs, prostate cancer patients have a turnaround "In recent years, the treatment pattern of advanced prostate cancer is rapidly changing.
At present, a variety of therapeutic drugs have been approved for the treatment of advanced prostate cancer, including the new anti-androgen drug abiraterone, Enzalutamide, apatamide, dalolutamide, etc.
, drugs docetaxel and cabazitaxel that inhibit the depolymerization of microtubules and promote tubulin polymerization, as well as the drug radium-223 for bone metastasis, targeted drive Precise targeted drugs for gene mutations such as the PARP inhibitor olaparib, and the drug Cyprusel-T, which involves immune mechanisms, and so on.
"In the view of Professor Ye Lefu, many new drugs have been approved for the market, which can help prostate cancer.
The patient's survival brought a turnaround.
As my country’s aging process accelerates, the incidence of prostate cancer may become higher and higher, and the number of patients with advanced prostate cancer will also increase.
It is imperative to strengthen the standardized management of advanced prostate cancer throughout the process.
In this evolving field, how to choose the right medicine is the key to maximizing the benefits of patients.
Professor Ye Lefu believes that prostate cancer should be managed as a chronic disease.
With the emergence of new drugs, there are more and more choices of drugs, which may cause a lot of confusion to doctors and patients.
At this time, a treatment plan should be developed according to the specific situation of the patient.
"When to use a single drug, when to use a combination therapy, which drug is combined with a combination therapy, etc.
, all need to be determined according to the specific situation.
" In addition, the diagnosis and treatment of prostate patients needs to be combined with various departments to carry out multidisciplinary collaboration.
(MDT), and manage patients throughout the process.
With the continuous development of new drugs, urological oncologists have a better understanding of optimizing the treatment plan for advanced prostate cancer, which will help to improve the overall survival benefits of patients.
"In the future, the treatment of prostate cancer should be based on precision treatment, with genetic testing, molecular marker testing, etc.
, to guide patients on medication.
" The efficacy of patients and the confidence of doctors In the past five years, the diagnosis and treatment of advanced prostate cancer in China has occurred.
Earth-shaking changes. "Five years ago, for patients with advanced prostate cancer, there were no particularly good drugs in China except for endocrine therapy.
When patients lost their effect on endocrine therapy and entered CRPC, they entered an irreversible stage with a very short life expectancy.
" Five years Previously, Abiraterone was listed in China, which brought good news to Chinese prostate cancer patients and saved many patients' lives.
After the price reduction of medical insurance, Abiraterone became a common medicine for prostate cancer patients in the Department of Urology of Provincial Hospitals.
The advent of the new program will inevitably bring more hope of survival to patients and give doctors more confidence in treatment.
Since Abiraterone was launched in China, it has accumulated a considerable number of patients, and its safety and effectiveness are worthy of recognition.
"Our hospital has used abiraterone for four to five years.
There are quite a lot of patients.
" Professor Ye Lefu remembered that a prostate cancer patient once saw in the literature that abiraterone can treat prostate cancer.
At that time, abiraterone was not available in China.
After being listed on the market, the patients purchased them abroad through various channels.
After a period of treatment, the patients’ ascites and lower extremity edema miraculously disappeared.
Professor Ye Lefu left a deep impression and confidence in treating such patients.
Today, the patient has been taking the drug for more than 6 years and still continues to benefit.
Although there are still many difficulties in the diagnosis and treatment of prostate cancer, it is believed that in the future, under the guidance of Professor Ye Lefu, more and more prostate cancer patients will benefit from the development of new drugs and achieve long-term survival.
Expert Profile Professor Ye Lefu, Chief Physician, Professor, and Doctoral Tutor of Urology at Fujian Provincial Hospital, Deputy Director of Urology at Fujian Provincial Hospital (in charge of work) and Deputy Director of Surgery at Fujian Provincial Jinshan Hospital, Chinese Medical Association Urology National Committee Member of the Chinese Medical Doctor Association Urology Branch National Committee Member of the Urology Branch of Fujian Medical Doctor AssociationVice Chairman of the Urology and Male Reproductive Oncology Committee of Fujian Anticancer AssociationVice Chairman of the Standing Committee and Transplantation Group of the Urology Branch of Fujian Medical Association Deputy Leader of the Urology Branch of Fujian Strait Medical and Health Exchange AssociationVice Chairman of the Organ Transplant Branch of Fujian Medical Association Member of the International Urolithiasis Alliance Member of the Urolithiasis Association of China Medical Care International Exchange Promotion Committee Member of the Urological Health Promotion Branch of the Cross-Strait Medical and Health Exchange Association Urology Department Member of the Professional Committee Member of the Prostate Diseases Group of the Urology Committee of the Chinese Integrative Medicine Association, serving as the young editorial board member of the "Journal of Modern Urology", the electronic edition of the "Journal of Urology" Professional and research direction: minimally invasive technology in urology (including robotics , Laparoscopy, percutaneous nephroscope, flexible ureteroscopy), good at diagnosis and treatment of urinary system tumors, stones, and benign prostatic hyperplasia References: [1]GLOBAL CANCER OBSERVATORY: Prostate Cancer.
Cancer Today.
http://gco.
iarc.
fr /today/data/pdf/fact-sheets/cancers/cancer-fact-sheets-19.
pdf.
Published 2018.
Accessed December 2020.
Listen to Professor Ye Lefu's talk about prostate cancer! In 1937, the legendary Nanyang overseas Chinese, Mr.
Hu Wenhu, donated funds to build the Fujian Provincial Hospital.
For more than 80 years, after several generations of unremitting efforts, the Fujian Provincial Hospital has developed into a clinical diagnosis and treatment, medical research, medical education, and preventive health care provider in Fujian Province.
center.
In 1972, under the leadership of Professor Chen Zifu, the Department of Urology of Fujian Provincial Hospital was established as an independent department.
After decades of development, the Department of Urology has grown and developed.
The quality of minimally invasive surgery has reached the domestic advanced level, ranking the leading position in the province.
Overseas Chinese patients return home for diagnosis and treatment.
"At present, our department has 3 wards, more than 140 beds, more than 40 doctors, and the sub-specialties are very complete, and we have recently resumed kidney transplantation related work.
" Professor Ye Lefu, deputy director of the Department of Urology, Fujian Provincial Hospital introduced Tao.
As an expert in urology at Fujian Provincial Hospital, Professor Ye Lefu has rich experience in diagnosis and treatment of various urinary diseases, especially prostate cancer.
He introduced to us the characteristics of the department and the status quo and challenges of prostate cancer diagnosis and treatment.
Advanced technology makes treatment the icing on the cake.
The Department of Urology, Fujian Provincial Hospital is one of the first domestic urological laparoscopic surgery units to carry out transabdominal pathways.
It is the first in Fujian Province to carry out laparoscopic nephron-sparing nephrectomy and giant adrenal tumor resection.
Minimally invasive techniques such as surgery and laparoscopic inguinal lymph node dissection.
Professor Ye Lefu introduced that the current department focuses on minimally invasive surgery and has formed its own characteristics.
"We have carried out some complicated kidney-saving operations early on, such as ultrasound-guided partial nephrectomy, laparoscopic radical cystectomy, total laparoscopic urinary diversion, and so on.
In October 2020, the Department of Urology introduced the province’s first fourth-generation Da Vinci robot (XI).
Professor Ye Lefu led the team to carry out three consecutive partial nephrectomy procedures, marking the entry of the Department of Urology of Fujian Provincial Hospital The era of robotic surgery.
"After the practice of surgery, I feel that the Da Vinci robot can make the surgery more minimally invasive, further reduce the complications of the surgery, and the patient recovers faster.
"In the treatment and scientific research of urinary system tumors, Professor Ye Lefu’s team is also actively carrying out scientific research and research on molecular classification, neoadjuvant chemotherapy, postoperative adjuvant therapy, and neoadjuvant endocrine therapy for prostate cancer.
Better treatment.
Early screening and early benefit.
Among all prostate diseases, prostate cancer is especially popular among elderly men, and it has gradually become a major stubborn disease that endangers the health of elderly men.
Prostate cancer is the second most common disease in men worldwide.
Common malignant tumors are also the fifth most common cause of cancer-related deaths in men [1].
Professor Ye Lefu introduced that most of the prostate cancer patients in the Department of Urology of Provincial Hospitals are middle-advanced patients, and relatively few early-stage patients.
But with With the improvement of people’s awareness of screening and the advancement of screening methods in recent years, the number of patients with early prostate cancer has gradually increased.
"In general, the age of onset has a trend of getting younger, and the incidence has gradually increased.
the trend of.
"Professor Ye Lefu said that early radical treatment of patients with surgery or radiotherapy can achieve very good therapeutic effects, and even some early patients can continue to benefit by adopting close follow-up.
"The current difficulty is targeting local areas.
Advanced or metastatic prostate cancer.
For patients with locally advanced prostate cancer, comprehensive treatment can be used; for advanced patients, long-term treatment based on endocrine therapy is recommended; for patients with metastatic castration-resistant prostate cancer (mCRPC), the current treatment effect is not ideal Although there are many new drugs coming out, the prognosis of patients is not good.
"Professor Ye Lefu concluded.
With the advent of new drugs, prostate cancer patients have a turnaround "In recent years, the treatment pattern of advanced prostate cancer is rapidly changing.
At present, a variety of therapeutic drugs have been approved for the treatment of advanced prostate cancer, including the new anti-androgen drug abiraterone, Enzalutamide, apatamide, dalolutamide, etc.
, drugs docetaxel and cabazitaxel that inhibit the depolymerization of microtubules and promote tubulin polymerization, as well as the drug radium-223 for bone metastasis, targeted drive Precise targeted drugs for gene mutations such as the PARP inhibitor olaparib, and the drug Cyprusel-T, which involves immune mechanisms, and so on.
"In the view of Professor Ye Lefu, many new drugs have been approved for the market, which can help prostate cancer.
The patient's survival brought a turnaround.
As my country’s aging process accelerates, the incidence of prostate cancer may become higher and higher, and the number of patients with advanced prostate cancer will also increase.
It is imperative to strengthen the standardized management of advanced prostate cancer throughout the process.
In this evolving field, how to choose the right medicine is the key to maximizing the benefits of patients.
Professor Ye Lefu believes that prostate cancer should be managed as a chronic disease.
With the emergence of new drugs, there are more and more choices of drugs, which may cause a lot of confusion to doctors and patients.
At this time, a treatment plan should be developed according to the specific situation of the patient.
"When to use a single drug, when to use a combination therapy, which drug is combined with a combination therapy, etc.
, all need to be determined according to the specific situation.
" In addition, the diagnosis and treatment of prostate patients needs to be combined with various departments to carry out multidisciplinary collaboration.
(MDT), and manage patients throughout the process.
With the continuous development of new drugs, urological oncologists have a better understanding of optimizing the treatment plan for advanced prostate cancer, which will help to improve the overall survival benefits of patients.
"In the future, the treatment of prostate cancer should be based on precision treatment, with genetic testing, molecular marker testing, etc.
, to guide patients on medication.
" The efficacy of patients and the confidence of doctors In the past five years, the diagnosis and treatment of advanced prostate cancer in China has occurred.
Earth-shaking changes. "Five years ago, for patients with advanced prostate cancer, there were no particularly good drugs in China except for endocrine therapy.
When patients lost their effect on endocrine therapy and entered CRPC, they entered an irreversible stage with a very short life expectancy.
" Five years Previously, Abiraterone was listed in China, which brought good news to Chinese prostate cancer patients and saved many patients' lives.
After the price reduction of medical insurance, Abiraterone became a common medicine for prostate cancer patients in the Department of Urology of Provincial Hospitals.
The advent of the new program will inevitably bring more hope of survival to patients and give doctors more confidence in treatment.
Since Abiraterone was launched in China, it has accumulated a considerable number of patients, and its safety and effectiveness are worthy of recognition.
"Our hospital has used abiraterone for four to five years.
There are quite a lot of patients.
" Professor Ye Lefu remembered that a prostate cancer patient once saw in the literature that abiraterone can treat prostate cancer.
At that time, abiraterone was not available in China.
After being listed on the market, the patients purchased them abroad through various channels.
After a period of treatment, the patients’ ascites and lower extremity edema miraculously disappeared.
Professor Ye Lefu left a deep impression and confidence in treating such patients.
Today, the patient has been taking the drug for more than 6 years and still continues to benefit.
Although there are still many difficulties in the diagnosis and treatment of prostate cancer, it is believed that in the future, under the guidance of Professor Ye Lefu, more and more prostate cancer patients will benefit from the development of new drugs and achieve long-term survival.
Expert Profile Professor Ye Lefu, Chief Physician, Professor, and Doctoral Tutor of Urology at Fujian Provincial Hospital, Deputy Director of Urology at Fujian Provincial Hospital (in charge of work) and Deputy Director of Surgery at Fujian Provincial Jinshan Hospital, Chinese Medical Association Urology National Committee Member of the Chinese Medical Doctor Association Urology Branch National Committee Member of the Urology Branch of Fujian Medical Doctor AssociationVice Chairman of the Urology and Male Reproductive Oncology Committee of Fujian Anticancer AssociationVice Chairman of the Standing Committee and Transplantation Group of the Urology Branch of Fujian Medical Association Deputy Leader of the Urology Branch of Fujian Strait Medical and Health Exchange AssociationVice Chairman of the Organ Transplant Branch of Fujian Medical Association Member of the International Urolithiasis Alliance Member of the Urolithiasis Association of China Medical Care International Exchange Promotion Committee Member of the Urological Health Promotion Branch of the Cross-Strait Medical and Health Exchange Association Urology Department Member of the Professional Committee Member of the Prostate Diseases Group of the Urology Committee of the Chinese Integrative Medicine Association, serving as the young editorial board member of the "Journal of Modern Urology", the electronic edition of the "Journal of Urology" Professional and research direction: minimally invasive technology in urology (including robotics , Laparoscopy, percutaneous nephroscope, flexible ureteroscopy), good at diagnosis and treatment of urinary system tumors, stones, and benign prostatic hyperplasia References: [1]GLOBAL CANCER OBSERVATORY: Prostate Cancer.
Cancer Today.
http://gco.
iarc.
fr /today/data/pdf/fact-sheets/cancers/cancer-fact-sheets-19.
pdf.
Published 2018.
Accessed December 2020.
